About Genomic Valley Biotech
Genomic Valley Biotech is a publicly listed company based in Jhajjar (India) founded in 1994. RD company focused on plant tissue cultured plants. Its Indian entity Genomic Valley Biotech Limited reported revenue of ₹27 Lakh. Its focus areas include Food and Agriculture and Crop Research and Training Services.
Company details
Genomic Valley Biotech was founded in 1994 and is based in Jhajjar, India. Operations center on research and development within the biotechnology sector, specifically plant tissue culture techniques. Services include the production and propagation of tissue-cultured plants for agricultural and horticultural applications. The company is led by Managing Director and Chairman Yogesh Agrawal. Activities are conducted to support advancements in plant propagation and genetic stability.
- Headquarters Jhajjar, India
- Stage Public
- SectorsAgriculture
- Email••••••••
- Phone•••• ••••
- Website genomicvalley.com
- Legal Name Genomic Valley Biotech Ltd
- Market Cap₹15.31 Cr
GVBL · BSE
- Share Price₹52.63
+4.99% today
- Revenue₹0.27 Cr
FY 2025-26 · -67.9% YoY
- EBITDA₹0.05 Cr
Margin 18.5%
- Net Profit₹0.04 Cr
FY 2025-26 · -88.2% YoY
Associated legal entities of Genomic Valley Biotech
Genomic Valley Biotech operates through Genomic Valley Biotech Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Limited Listed CIN L01122HR1994PLC033029 | Active | 16 May 1994 | Jhajjar, Haryana | ₹0.3 Cr | 5 | 6 | View details |
Board of directors of Genomic Valley Biotech Limited (Genomic Valley Biotech)
Genomic Valley Biotech Limited is the primary company behind Genomic Valley Biotech. The board of Genomic Valley Biotech Limited currently have 4 directors; the longest-serving is Yogesh Agrawal, appointed in 2015. 18 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Yogesh Agrawal DIN 01165288 | Managing Director | 07 Sep 2015 | 11 yrs 2 mo | Genomic Valley Biotech Limited |
| Parul Agrawal DIN 01165188 | Director | 14 Feb 2024 | 2 yrs 8 mo | Genomic Valley Biotech Limited |
| Satendra Kumar Goyal DIN 08767544 | Director | 09 May 2024 | 2 yrs 6 mo | Genomic Valley Biotech Limited |
| Yogainder Kumar Gupta DIN 03094998 | Director | 30 May 2025 | 1 yr 5 mo | Genomic Valley Biotech Limited |
People of Genomic Valley Biotech
1 people are tracked at Genomic Valley Biotech (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Managing Director & Chairman | Leadership |
Complete people profiles for Genomic Valley Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Genomic Valley Biotech
Genomic Valley Biotech is a publicly listed company on the BSE with ticker symbol GVBL in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Jul 2015
- Listed onBSE: 539206
- Listed entityGenomic Valley Biotech Ltd
- Exchange sectorHealth technology
- ISININE574D01010
- Share price₹34.30 (+3.94% on the day) · 2026-10-14
- Volume (last session)501
Financials of Genomic Valley Biotech
Exchange-reported figures of Genomic Valley Biotech Limited, the listed company behind Genomic Valley Biotech (BSE: GVBL).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.27 | 0.84 | 0.17 | 2.72 | 0.07 | 0.21 | 0.85 |
| Revenue growth | -67.9% | +394.1% | -93.8% | +3785.7% | -66.7% | -75.3% | - |
| EBITDA | 0.05 | 0.43 | 0.02 | 0.62 | (0.37) | (0.14) | 0.55 |
| EBITDA margin | +18.5% | +51.2% | +11.8% | +22.8% | -528.6% | -66.7% | +64.7% |
| Profit before tax | 0.05 | 0.43 | 0.02 | 0.65 | 0.01 | (0.51) | 0.20 |
| Net profit | 0.04 | 0.34 | 0.02 | 0.91 | (0.41) | (0.57) | 0.28 |
| Net profit margin | +14.8% | +40.5% | +11.8% | +33.5% | -585.7% | -271.4% | +32.9% |
| EPS (₹) | 0.10 | 1.17 | 0.05 | 2.12 | (0.03) | (1.83) | 0.94 |
| Balance sheet | |||||||
| Total assets | - | 3.90 | 3.54 | 3.53 | 3.58 | 6.75 | 7.24 |
| Net worth | - | 3.89 | 3.54 | 3.52 | 2.87 | 4.48 | 5.04 |
| Total debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 1.55 | 1.48 |
| Cash & bank | - | 0.05 | 0.01 | 0.04 | 0.00 | 0.01 | 0.04 |
| Net working capital | - | 2.16 | 2.12 | 1.68 | 0.93 | (0.71) | (0.37) |
| Cash flow | |||||||
| Cash from operations | - | 0.03 | (0.02) | (0.78) | (2.13) | 1.48 | 0.44 |
| Cash from investing | - | 0.01 | (0.02) | 1.52 | 3.67 | (1.58) | (0.47) |
| Cash from financing | - | 0.00 | 0.00 | (0.70) | (1.55) | 0.07 | 0.00 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.04 | 0.04 | 0.05 | 0.09 | 0.09 | 0.26 | 0.22 |
| Revenue growth (YoY) | -100.0% | -55.6% | -84.6% | -77.3% | -57.1% | -43.8% | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.02 | 0.02 | 0.03 | 0.04 | 0.09 | 0.06 | 0.26 | 0.06 |
| EBITDA | (0.02) | 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | 0.00 | 0.16 |
| EBITDA margin | - | +50.0% | +25.0% | +20.0% | 0.0% | +33.3% | 0.0% | +72.7% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.02) | 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | 0.00 | 0.16 |
| Tax | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.04 | 0.04 | 0.05 | 0.09 | 0.09 | 0.26 | 0.22 |
| Revenue growth (YoY) | -100.0% | -55.6% | -84.6% | -77.3% | -57.1% | -43.8% | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.02 | 0.02 | 0.03 | 0.04 | 0.09 | 0.06 | 0.26 | 0.06 |
| EBITDA | (0.02) | 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | 0.00 | 0.16 |
| EBITDA margin | - | +50.0% | +25.0% | +20.0% | 0.0% | +33.3% | 0.0% | +72.7% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.02) | 0.02 | 0.01 | 0.01 | 0.00 | 0.03 | 0.00 | 0.16 |
| Tax | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.27 | 0.84 | 0.17 | 2.72 | 0.07 | 0.21 | 0.85 |
| Revenue growth | -67.9% | +394.1% | -93.8% | +3785.7% | -66.7% | -75.3% | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.04 | 0.50 | 0.00 | 0.01 |
| Total expenses | 0.22 | 0.41 | 0.15 | 2.10 | 0.44 | 0.35 | 0.30 |
| Employee cost | 0.00 | 0.12 | 0.04 | 0.15 | 0.14 | 0.09 | 0.18 |
| EBITDA | 0.05 | 0.43 | 0.02 | 0.62 | (0.37) | (0.14) | 0.55 |
| EBITDA margin | +18.5% | +51.2% | +11.8% | +22.8% | -528.6% | -66.7% | +64.7% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.08 | 0.19 | 0.18 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.18 | 0.18 |
| Profit before tax | 0.05 | 0.43 | 0.02 | 0.65 | 0.01 | (0.51) | 0.20 |
| Tax | 0.01 | 0.09 | 0.00 | 0.00 | 0.01 | 0.06 | (0.08) |
| Net profit | 0.04 | 0.34 | 0.02 | 0.91 | (0.41) | (0.57) | 0.28 |
| Net profit margin | +14.8% | +40.5% | +11.8% | +33.5% | -585.7% | -271.4% | +32.9% |
| EPS (₹) | 0.10 | 1.17 | 0.05 | 2.12 | (0.03) | (1.83) | 0.94 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Reserves & surplus | - | 0.84 | 0.49 | 0.47 | (0.18) | 1.43 | 1.99 |
| Shareholders' funds (net worth) | - | 3.89 | 3.54 | 3.52 | 2.87 | 4.48 | 5.04 |
| Secured loans | - | 0.00 | 0.00 | 0.00 | 0.00 | 1.55 | 1.48 |
| Unsecured loans | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 1.55 | 1.48 |
| Total liabilities | - | 3.90 | 3.54 | 3.53 | 3.58 | 6.75 | 7.24 |
| Assets | |||||||
| Gross block | - | 0.01 | 0.00 | 0.48 | 2.57 | 6.60 | 5.02 |
| Net block | - | 0.01 | 0.00 | 0.00 | 1.75 | 5.86 | 4.47 |
| Capital work in progress | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.49 | 0.49 |
| Investments | - | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | - | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 |
| Sundry debtors | - | 2.21 | 2.53 | 2.22 | 0.00 | 0.06 | 0.10 |
| Cash & bank balances | - | 0.05 | 0.01 | 0.04 | 0.00 | 0.01 | 0.04 |
| Loans & advances | - | 0.08 | 0.37 | 0.32 | 1.14 | 0.09 | 0.14 |
| Total current assets | - | 2.62 | 2.91 | 2.58 | 1.14 | 0.16 | 0.40 |
| Total current liabilities | - | 0.46 | 0.79 | 0.90 | 0.21 | 0.87 | 0.77 |
| Net working capital | - | 2.16 | 2.12 | 1.68 | 0.93 | (0.71) | (0.37) |
| Total assets | - | 3.90 | 3.54 | 3.53 | 3.58 | 6.75 | 7.24 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 0.01 | 0.04 | 0.00 | 0.01 | 0.04 | 0.08 |
| Net cash from operating activities | - | 0.03 | (0.02) | (0.78) | (2.13) | 1.48 | 0.44 |
| Net cash from investing activities | - | 0.01 | (0.02) | 1.52 | 3.67 | (1.58) | (0.47) |
| Net cash from financing activities | - | 0.00 | 0.00 | (0.70) | (1.55) | 0.07 | 0.00 |
| Net change in cash | - | 0.04 | (0.04) | 0.04 | (0.01) | (0.03) | (0.04) |
| Closing cash | - | 0.05 | 0.01 | 0.04 | 0.00 | 0.01 | 0.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -67.9% | +394.1% | -93.8% | +3785.7% | -66.7% | -75.3% | - |
| EBITDA growth | -88.4% | +2050.0% | -96.8% | +267.6% | -164.3% | -125.5% | - |
| PBT growth | -88.4% | +2050.0% | -96.9% | +6400.0% | +9998.0% | - | -16.7% |
| Net income growth | -88.2% | +1600.0% | -97.8% | +322.0% | +28.1% | -303.6% | - |
| Revenue CAGR (3Y) | -53.7% | +128.9% | -6.8% | +47.4% | -58.7% | -29.1% | +24.5% |
| EBITDA CAGR (3Y) | -56.8% | - | - | +4.1% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +14.8% | +40.5% | +11.8% | +23.9% | 0.0% | -271.4% | +32.9% |
| Return on capital employed | - | +12.1% | +0.6% | +25.7% | 0.0% | 0.0% | +5.4% |
| Return on net worth | - | +9.7% | +0.6% | +28.5% | 0.0% | 0.0% | +5.8% |
| Debt / equity | - | 0.00 | 0.00 | 0.00 | 0.21 | 0.32 | 0.30 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.21 | 0.32 | 0.30 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | -8.89 | -54.55 | 48.65 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 168.00 | 0.71 | 1.78 | 0.02 | 0.04 | 0.17 |
| Inventory turnover | - | 6.00 | 0.00 | 0.00 | 0.00 | 3.50 | 7.08 |
| Debtors turnover | - | 0.35 | 0.07 | 2.45 | 2.33 | 2.63 | 10.63 |
| EPS (₹) | 0.10 | 1.17 | 0.05 | 2.12 | (0.03) | (1.83) | 0.94 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 12.76 | 11.60 | 11.55 | 9.42 | 14.69 | 16.52 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genomic Valley Biotech
Complete news archive for Genomic Valley Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genomic Valley Biotech
Genomic Valley Biotech was founded in 1994.
Genomic Valley Biotech is headquartered in Jhajjar, India. It is registered at Jhajjar, Haryana, India.
The primary company behind Genomic Valley Biotech, Genomic Valley Biotech Limited, reported revenue of ₹27 Lakh for FY 2026, down 68% year on year.
Genomic Valley Biotech was founded in 1994 and is based in Jhajjar, India. Operations center on research and development within the biotechnology sector, specifically plant tissue culture techniques. Services include the production and propagation of tissue-cultured plants for agricultural and horticultural applications. The company is led by Managing Director and Chairman Yogesh Agrawal. Activities are conducted to support advancements in plant propagation and genetic stability.
Yes, Genomic Valley Biotech is publicly traded on BSE under the ticker symbol GVBL.
Genomic Valley Biotech operates through Genomic Valley Biotech Limited.
The legal entities of Genomic Valley Biotech currently have 5 directors, including Yogesh Agrawal, Satendra Kumar Goyal, Parul Agrawal and others.